Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124310) titled 'Dalpiciclib with or without Camrelizumab in patients with advanced Intrahepatic Cholangiocarcinoma after failure or intolerance of first-line therapy: A prospective, double-Cohort, phase ?b/? study' on May 10.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
Intrahepatic cholangiocarcinoma
Intervention:
Queue 1 (Darsilim Single Drug):Receive darzalex monotherapy. The recommended dose of darzalex is 150 mg, taken orally daily from D1 to D21. Each cycle lasts for 4 weeks (28 days).
Queue 2 (Dasilei combined with Carlimabucil...